1,216 followers
RT @quequesierra: (NEJM) Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia Interesante estudio. Un par de limita…
So far, Altmetric has seen
173 X posts from 153 X users, with an upper bound of 1,518,674 followers.
697 followers
2. La HAS a accordé une ASMR mineure : https://t.co/KWTnuQfgaP à l’association VENCLYXTO® + rituximab vs bendamustine + rituximab sur la base de la survie sans progression dans l’essai MURANO : https://t.co/irHGSRI7eZ un critère de jugement indirect https…
2,141 followers
For me this is one of the biggest risks to investment in $ARQL and $SNSS (long both). The bar is high with respect to efficacy.
2,141 followers
CLL pts are coming off Ibrutinib by the truckload for intolerance and resistance. Heme/oncs need tools for subsequent lines of Tx. For 17p deleted, Venetoclax has shown very good efficacy. (MURANO) Venetoclax also is agnostic to C481s mutational status…